Trade FibroGen, Inc - FGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.03 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.3 |
| Open | 0.29 |
| 1-Year Change | -71.84% |
| Day's Range | 0.29 - 0.31 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.30 | 0.01 | 3.45% | 0.29 | 0.30 | 0.29 |
| Apr 23, 2025 | 0.29 | 0.00 | 0.00% | 0.29 | 0.30 | 0.29 |
| Apr 22, 2025 | 0.28 | 0.01 | 3.70% | 0.27 | 0.29 | 0.27 |
| Apr 21, 2025 | 0.27 | -0.01 | -3.57% | 0.28 | 0.28 | 0.26 |
| Apr 10, 2025 | 0.25 | 0.00 | 0.00% | 0.25 | 0.25 | 0.25 |
| Apr 9, 2025 | 0.24 | 0.00 | 0.00% | 0.24 | 0.24 | 0.24 |
| Apr 4, 2025 | 0.26 | 0.00 | 0.00% | 0.26 | 0.26 | 0.26 |
| Mar 28, 2025 | 0.30 | -0.02 | -6.25% | 0.32 | 0.32 | 0.30 |
| Mar 27, 2025 | 0.32 | 0.00 | 0.00% | 0.32 | 0.32 | 0.32 |
| Mar 26, 2025 | 0.33 | 0.00 | 0.00% | 0.33 | 0.33 | 0.32 |
| Mar 25, 2025 | 0.34 | 0.00 | 0.00% | 0.34 | 0.34 | 0.34 |
| Mar 24, 2025 | 0.34 | 0.04 | 13.33% | 0.30 | 0.34 | 0.30 |
| Mar 21, 2025 | 0.30 | -0.02 | -6.25% | 0.32 | 0.32 | 0.30 |
| Mar 20, 2025 | 0.33 | 0.00 | 0.00% | 0.33 | 0.33 | 0.33 |
| Mar 19, 2025 | 0.33 | 0.00 | 0.00% | 0.33 | 0.33 | 0.33 |
| Mar 18, 2025 | 0.32 | -0.01 | -3.03% | 0.33 | 0.35 | 0.29 |
| Mar 17, 2025 | 0.42 | 0.00 | 0.00% | 0.42 | 0.42 | 0.39 |
| Mar 14, 2025 | 0.41 | 0.00 | 0.00% | 0.41 | 0.43 | 0.41 |
| Mar 13, 2025 | 0.40 | -0.05 | -11.11% | 0.45 | 0.45 | 0.39 |
| Mar 12, 2025 | 0.44 | 0.05 | 12.82% | 0.39 | 0.46 | 0.39 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
FibroGen, Inc Company profile
About FibroGen Inc
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com